Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
PLoS One. 2013;8(1):e52178. doi: 10.1371/journal.pone.0052178. Epub 2013 Jan 8.
The increasing incidence of small renal tumors in an aging population with comorbidities has stimulated the development of minimally invasive treatments. This study aimed to assess the efficacy and demonstrate feasibility of multimodality imaging of intratumoral administration of holmium-166 microspheres ((166)HoAcAcMS). This new technique locally ablates renal tumors through high-energy beta particles, while the gamma rays allow for nuclear imaging and the paramagnetism of holmium allows for MRI.
(166)HoAcAcMS were administered intratumorally in orthotopic renal tumors (Balb/C mice). Post administration CT, SPECT and MRI was performed. At several time points (2 h, 1, 2, 3, 7 and 14 days) after MS administration, tumors were measured and histologically analyzed. Holmium accumulation in organs was measured using inductively coupled plasma mass spectrometry.
(166)HoAcAcMS were successfully administered to tumor bearing mice. A striking near-complete tumor-control was observed in (166)HoAcAcMS treated mice (0.10±0.01 cm(3) vs. 4.15±0.3 cm(3) for control tumors). Focal necrosis and inflammation was present from 24 h following treatment. Renal parenchyma outside the radiated region showed no histological alterations. Post administration CT, MRI and SPECT imaging revealed clear deposits of (166)HoAcAcMS in the kidney.
Intratumorally administered (166)HoAcAcMS has great potential as a new local treatment of renal tumors for surgically unfit patients. In addition to strong cancer control, it provides powerful multimodality imaging opportunities.
老龄化伴有合并症的人群中小肾脏肿瘤的发病率不断增加，这刺激了微创治疗的发展。本研究旨在评估钬-166 醋酸盐微球（（166）HoAcAcMS）瘤内注射的多模态成像的疗效和可行性。这种新技术通过高能β粒子局部消融肾肿瘤，同时伽马射线允许核成像，钬的顺磁性允许 MRI。
（166）HoAcAcMS 经皮瘤内注射于原位肾脏肿瘤（Balb/C 小鼠）。注射后行 CT、SPECT 和 MRI 检查。在 MS 给药后几个时间点（2 h、1、2、3、7 和 14 天），测量肿瘤并进行组织学分析。使用电感耦合等离子体质谱法测量器官中的钬积累。
（166）HoAcAcMS 成功地施用于荷瘤小鼠。在（166）HoAcAcMS 治疗的小鼠中观察到显著的近乎完全的肿瘤控制（0.10±0.01 cm3 对对照肿瘤的 4.15±0.3 cm3）。治疗后 24 小时出现局灶性坏死和炎症。辐射区域外的肾实质未显示出组织学改变。MS 给药后的 CT、MRI 和 SPECT 成像显示在肾脏中清楚地沉积了（166）HoAcAcMS。
瘤内注射（166）HoAcAcMS 具有作为一种新的局部治疗不适合手术的肾肿瘤的巨大潜力。除了强大的癌症控制外，它还提供了强大的多模态成像机会。
